SCHEMBL4162862

SCHEMBL4162862

COc1ccc(N2CCC(N3CCCCC3)CC2)cc1-c1cnn2c(N)c(-c3cccc(Cl)c3)c(C)nc12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FYN P06241 1/20 0.43
KMT2A Q03164 5/20 0.40
MEN1 O00255 4/20 0.40
NPC1 O15118 3/20 0.40
CASP3 P42574 2/20 0.40
SENP8 Q96LD8 2/20 0.40
SENP7 Q9BQF6 2/20 0.40
SENP6 Q9GZR1 2/20 0.40
RET P07949 3/20 0.40
KIF5B P33176 3/20 0.40
KDR P35968 3/20 0.40
ETV6 P41212 3/20 0.40
CCDC6 Q16204 3/20 0.40
DYRK3 O43781 1/20 0.40
CCNT1 O60563 1/20 0.40
CDK9 P50750 1/20 0.40
DYRK1A Q13627 1/20 0.40
DYRK2 Q92630 1/20 0.40
DYRK1B Q9Y463 1/20 0.40
ALK Q9UM73 5/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4177518 0.99 FYN (0.44) FYNKMT2AMEN1NPC1CASP3
SCHEMBL4170130 0.93 ALK (0.45) FYNRETKIF5BKDRETV6
SCHEMBL4173026 0.92 RET (0.46) FYNKMT2AMEN1NPC1CASP3
SCHEMBL4177509 0.91 LCK (0.39) FYNKMT2AMEN1NPC1CASP3
SCHEMBL4180131 0.90 FYN (0.46) FYNKMT2AMEN1NPC1CASP3
SCHEMBL4176946 0.89 MEN1 (0.44) FYNKMT2AMEN1NPC1CASP3
SCHEMBL4167171 0.88 FYN (0.44) FYNKMT2AMEN1NPC1CASP3
SCHEMBL4171407 0.88 MEN1 (0.48) FYNKMT2AMEN1NPC1CASP3
SCHEMBL4171309 0.87 LCK (0.50) FYNKMT2AMEN1NPC1CASP3
SCHEMBL4173163 0.86 FYN (0.47) FYNKMT2AMEN1NPC1CASP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090069315-A1 Use of Pyrazolo(1,5A)Pyrimidin-7-YL Amine Derivatives in the Treatment of Neurological Disorders SIVASANKARAN RAJEEV 2009-03-12 US disclosed
US-20090069315-A1 Use of Pyrazolo(1,5A)Pyrimidin-7-YL Amine Derivatives in the Treatment of Neurological Disorders SIVASANKARAN RAJEEV 2009-03-12 US disclosed
US-20090069315-A1 Use of Pyrazolo(1,5A)Pyrimidin-7-YL Amine Derivatives in the Treatment of Neurological Disorders SIVASANKARAN RAJEEV 2009-03-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090069315-A1 Use of Pyrazolo(1,5A)Pyrimidin-7-YL Amine Derivatives in the Treatment of Neurological Disorders EPHA5, EPHA7, EPHA1 FYN 360/4885KMT2A 3248/4885MEN1 4377/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.